Omnicell, Inc. (NASDAQ:OMCL) Shares Acquired by Northern Trust Corp

Northern Trust Corp lifted its position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 14.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 565,026 shares of the company's stock after acquiring an additional 69,916 shares during the period. Northern Trust Corp owned 1.22% of Omnicell worth $25,155,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Smartleaf Asset Management LLC lifted its holdings in Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after purchasing an additional 273 shares in the last quarter. Johnson Financial Group Inc. acquired a new stake in shares of Omnicell in the fourth quarter valued at about $37,000. Van ECK Associates Corp lifted its stake in shares of Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after buying an additional 315 shares in the last quarter. Headlands Technologies LLC acquired a new position in Omnicell during the fourth quarter worth about $53,000. Finally, First Horizon Advisors Inc. boosted its position in Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after acquiring an additional 355 shares during the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Trading Up 0.7%

Shares of Omnicell stock traded up $0.20 during mid-day trading on Friday, hitting $28.28. The stock had a trading volume of 108,081 shares, compared to its average volume of 556,639. The firm has a 50-day moving average of $31.57 and a two-hundred day moving average of $39.64. The firm has a market cap of $1.32 billion, a P/E ratio of 104.84, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, beating analysts' consensus estimates of $0.16 by $0.10. The firm had revenue of $269.67 million for the quarter, compared to analysts' expectations of $260.18 million. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The firm's quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.03 earnings per share. Sell-side analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on OMCL shares. Benchmark cut their price objective on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Wells Fargo & Company upgraded Omnicell from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $31.00 to $35.00 in a research report on Wednesday. StockNews.com downgraded Omnicell from a "buy" rating to a "hold" rating in a research report on Saturday, May 3rd. Finally, JPMorgan Chase & Co. lowered their price objective on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, March 20th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $46.50.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.